The Anti-Vitiligo Effects of Feshurin In Vitro from and the Mechanism of Action

Overview

Journal Pharmaceuticals (Basel)

Publisher MDPI

Specialty Chemistry

Date 2024 Sep 28

PMID 39338414

Authors

Mayire Nueraihemaiti

Zang Deng

Khamidulla Kamoldinov

Niu Chao

Maidina Habasi

Haji Akber Aisa

Affiliations

Soon will be listed here.

Abstract

Background: Vitiligo is a complex disorder characterized by skin depigmentation; the canonical Wnt signaling pathway that involves -catenin plays a crucial role in promoting the melanin production in melanocytes. Targeted inhibition of the Janus kinase JAK-STAT pathway can effectively diminish the secretion of the chemokine C-X-C motif ligand CXCL10, thereby safeguarding melanocytes. has been applied as a treatment regimen for a long period; however, its use for the treatment of vitiligo has not been previously documented.

Methods: CCK-8 assay, Intracellular melanin content assay, Tyrosinase activity assay, Western blotting, qRT-PCR, and ELISA methods were employed. Using molecular docking verified the inhibitory effects of feshurin on the JAK1.

Results: The sesquiterpene coumarin feshurin was separated from . Feshurin was shown to induce GSK-3 phosphorylation, resulting in the translocation of -catenin into the nucleus. This translocation subsequently upregulated the transcription of microphthalmia-associated transcription factor (MITF), leading to increased tyrosinase activity and melanin production. In addition, feshurin inhibited the production of chemokine CXCL10 via the JAK-STAT signaling pathway, which was verified by molecular docking.

Conclusions: Based on these findings, it can be concluded that feshurin exhibits significant potential for the development of novel anti-vitiligo therapeutics.

Citing Articles

Mechanistic Insights into the Stimulatory Effect of Melanogenesis of 4-Methylcoumarin Derivatives in B16F10 Melanoma Cells.

Lee Y, Hyun C Int J Mol Sci. 2024; 25(22).

PMID: 39596485 PMC: 11594713. DOI: 10.3390/ijms252212421.

References

Zhou J, Ling J, Song J, Wang Y, Feng B, Ping F . Interleukin 10 protects primary melanocyte by activation of Stat-3 and PI3K/Akt/NF-κB signaling pathways. Cytokine. 2016; 83:275-281. DOI: 10.1016/j.cyto.2016.05.013. View

Speeckaert R, Caelenberg E, Belpaire A, Speeckaert M, van Geel N . Vitiligo: From Pathogenesis to Treatment. J Clin Med. 2024; 13(17). PMC: 11396398. DOI: 10.3390/jcm13175225. View

Ohta S, Ahmed A, Hirata T . Sesquiterpene coumarins from the roots of Ferula assa-foetida. Phytochemistry. 2001; 58(8):1289-95. DOI: 10.1016/s0031-9422(01)00324-7. View

Zhang L, Xu X, Chen S, Kang Y, Wang X, Zhang C . Increased Circulating CXCL10 in Non-Segmental Vitiligo Concomitant with Autoimmune Thyroid Disease and Alopecia Areata. Ann Dermatol. 2021; 31(4):393-402. PMC: 7992767. DOI: 10.5021/ad.2019.31.4.393. View

Jin Y, Roberts G, Ferrara T, Ben S, van Geel N, Wolkerstorfer A . Early-onset autoimmune vitiligo associated with an enhancer variant haplotype that upregulates class II HLA expression. Nat Commun. 2019; 10(1):391. PMC: 6344500. DOI: 10.1038/s41467-019-08337-4. View

Qi F, Liu F, Gao L . Janus Kinase Inhibitors in the Treatment of Vitiligo: A Review. Front Immunol. 2021; 12:790125. PMC: 8636851. DOI: 10.3389/fimmu.2021.790125. View

Prieux R, Ferrara F, Cervellati F, Guiotto A, Benedusi M, Valacchi G . Inflammasome involvement in CS-induced damage in HaCaT keratinocytes. In Vitro Cell Dev Biol Anim. 2022; 58(4):335-348. PMC: 9076721. DOI: 10.1007/s11626-022-00658-x. View

White C, Miller R . A Literature Review Investigating the Use of Topical Janus Kinase Inhibitors for the Treatment of Vitiligo. J Clin Aesthet Dermatol. 2022; 15(4):20-25. PMC: 9017670. View

Shah F, Patel S, Begum R, Dwivedi M . Emerging role of Tissue Resident Memory T cells in vitiligo: From pathogenesis to therapeutics. Autoimmun Rev. 2021; 20(8):102868. DOI: 10.1016/j.autrev.2021.102868. View

10.

Morelli M, Scarponi C, Mercurio L, Facchiano F, Pallotta S, Madonna S . Selective Immunomodulation of Inflammatory Pathways in Keratinocytes by the Janus Kinase (JAK) Inhibitor Tofacitinib: Implications for the Employment of JAK-Targeting Drugs in Psoriasis. J Immunol Res. 2018; 2018:7897263. PMC: 6276416. DOI: 10.1155/2018/7897263. View

11.

Cavalie M, Ezzedine K, Fontas E, Montaudie H, Castela E, Bahadoran P . Maintenance therapy of adult vitiligo with 0.1% tacrolimus ointment: a randomized, double blind, placebo-controlled study. J Invest Dermatol. 2014; 135(4):970-974. DOI: 10.1038/jid.2014.527. View

12.

Marchioro H, Silva de Castro C, Fava V, Sakiyama P, Dellatorre G, Miot H . Update on the pathogenesis of vitiligo. An Bras Dermatol. 2022; 97(4):478-490. PMC: 9263675. DOI: 10.1016/j.abd.2021.09.008. View

13.

Zhao Y, Hu Y, Shen Q, Xiong R, Song X, Guan C . DCUN1D1, a new molecule involved in depigmentation via upregulating CXCL10. Exp Dermatol. 2022; 32(4):457-468. DOI: 10.1111/exd.14732. View

14.

Razavi S, Janani M . A new ester coumarin from Ferula Persica wild, indigenous to Iran. Nat Prod Res. 2014; 29(8):717-21. DOI: 10.1080/14786419.2014.982650. View

15.

Jang E, Shin Y, Park H, Kim D, Jung C, Hong J . Anti-melanogenic activity of phytosphingosine via the modulation of the microphthalmia-associated transcription factor signaling pathway. J Dermatol Sci. 2017; 87(1):19-28. DOI: 10.1016/j.jdermsci.2017.03.011. View

16.

Boza J, Giongo N, Machado P, Horn R, Fabbrin A, Cestari T . Quality of Life Impairment in Children and Adults with Vitiligo: A Cross-Sectional Study Based on Dermatology-Specific and Disease-Specific Quality of Life Instruments. Dermatology. 2016; 232(5):619-625. DOI: 10.1159/000448656. View

17.

Bergqvist C, Ezzedine K . Vitiligo: A focus on pathogenesis and its therapeutic implications. J Dermatol. 2021; 48(3):252-270. DOI: 10.1111/1346-8138.15743. View

18.

Touni A, Shivde R, Echuri H, Abdel-Aziz R, Abdel-Wahab H, Kundu R . Melanocyte-keratinocyte cross-talk in vitiligo. Front Med (Lausanne). 2023; 10:1176781. PMC: 10235633. DOI: 10.3389/fmed.2023.1176781. View

19.

Migayron L, Boniface K, Seneschal J . Vitiligo, From Physiopathology to Emerging Treatments: A Review. Dermatol Ther (Heidelb). 2020; 10(6):1185-1198. PMC: 7649199. DOI: 10.1007/s13555-020-00447-y. View

20.

Motai T, Kitanaka S . Sesquiterpene phenylpropanoids from Ferula fukanensis and their nitric oxide production inhibitory effects. J Nat Prod. 2005; 68(3):365-8. DOI: 10.1021/np040215c. View